

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/586,023-Conf. #1717
				Filing Date	July 14, 2006
				First Named Inventor	Elisabeth Woltering
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	BHC 031067 83382(303989)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
/BK/ ↓	AA*	US-4,012,413	03-15-1977	Hester, Jr.	
	AB*	US-4,374,842	02-22-1983	Hirai et al.	
	AC*	US-4,476,133	10-09-1984	Hirai et al.	
	AD*	US-3,812,259	05-21-1974	Collins	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/BK/ ↓	BA	JP-05345785-A	12-27-1993	Yoshitomi Pharmaceutical et al.		
	BB	EP-875247-A1	11-04-1998	Tno		
	BC	EP-638560-A1	02-15-1995	Yoshitomi Pharmaceutical et al.		

Examiner Signature	/Bruck Kille/ (09/28/2010)	Date Considered	09/28/2010
-----------------------	----------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with §1.6(a)(4) on the date indicated below.	
Dated: <u>October 16, 2009</u>	Electronic Signature for Gabriel J. McCool: <u>/Gabriel J. McCool/</u>

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/586,023-Conf. #1717
				Filing Date	July 14, 2006
				First Named Inventor	Elisabeth Woltering
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	BHC 031067 83382(303989)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
/BK/	CA	G. Assmann et al.: "The Munster Heart Study (PROCAM)," European Heart Journal, Vol. 19, Supp. A., 1998, pp. A2-A11		
	CB	N. S. Watson et al.: "7 Squalene Synthase Inhibitors: Their Potential as Hypocholesterolaemic Agents," Progress in Medicinal Chemistry, Vol. 33, 1996, pp. 331-378		
	CC	H. Hiyoshi et al.: "Squalene Synthase Inhibitors Reduce Plasma Triglyceride Through a Low-Density Lipoprotein Receptor-Independent Mechanism," European Journal of Pharmacology, Vol. 431, 2001, pp. 345-352		
	CD	J. B. Jian et al.: "Synthesis and Biological Evaluation of 2-Styrylquinazolin-4(3H)-ones, a New Class of Antimitotic Anticancer Agents which Inhibit Tubulin Polymerization," J. Med. Chem., Vol. 33, 1990, pp. 171-1728		
	CE	T. Miki et al.: "Synthesis of Novel 4,1-Benzoxazepine Derivatives as Squalene Synthase Inhibitors and their Inhibition of Cholesterol Synthesis," J. Med. Chem., Vol. 45, 2002, pp. 4571-4580		
	CF	D. Papa et al.: "β-Aroylacrylic Acids," J. Amer. Chem. Soc., Vol. 70, 1948, pp. 3356-3360		
	CG	T. Miki et al.: "Novel 4,1-Benzoxazepine Derivatives with Potent Squalene Synthase Inhibitory Activities," Bioorganic & Medicinal Chemistry, Vol. 10, 2002, pp. 401-414		
	CH	D. Ma et al.: "Total Synthesis of (2S,2S,4R)-Plakoridine A," Tetrahedron Letters, Vol. 41, 2000, pp. 1947-1950		
	CI	K. H. Weber et al.: "Bistriazolooxazepine under -thiazepine, Pyrazolotriazolothiazepine und Thienotriazolooxazepine," Liebigs Ann. Chem., 1978, pp. 1250-1256		
	CJ	I W. Duncan et al.: "Determination of Free, Total, and Esterified Cholesterol by High-Performance Liquid Chromatography," Journal of Chromatography, Vol. 162, 1979, pp. 281-292		

Examiner Signature	/Bruck Kifle/ (09/28/2010)	Date Considered	09/28/2010
-----------------------	----------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/586,023-Conf. #1717
				Filing Date	July 14, 2006
				First Named Inventor	Elisabeth Woltering
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	BHC 031067 83382(303989)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/BK/	CK	H. Bischoff et al.: "Cerivastatin: Pharmacology of a Novel Synthetic and Highly Active HMG-CoA Reductase Inhibitor," Atherosclerosis, Vol 135, 1997, pp. 119-130	

Examiner Signature	/Bruck Kille/ (09/28/2010)	Date Considered	09/28/2010
-----------------------	----------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.